Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Eli Lilly and Company $LLY Stock Holdings Boosted by Farther Finance Advisors LLC
Eli Lilly and Company $LLY Shares Bought by CoreCap Advisors LLC
Eli Lilly and Company (NYSE:LLY) Stock Falls 1.6% - Here's Why
452 Eli Lilly and Company $LLY Shares Purchased by YHB Investment Advisors Inc. - Zolmax
Eli Lilly and Company $LLY Position Increased by CoreCap Advisors LLC - Stock Observer
978 Eli Lilly and Company $LLY Shares Acquired by Veracity Capital LLC - Zolmax
Eli Lilly and Company $LLY Stock Sold by Artemis Investment Management LLP
Eli Lilly and Company $LLY Stake Decreased by Meadowbrook Wealth Management LLC - Daily Political
InnoCare Pharma (SEHK:9969) Stock Dropped, So What Is Driving Attention Now?
Quintet Private Bank Europe S.A. Raises Stock Position in Eli Lilly and Company $LLY - Stock Observer
YHB Investment Advisors Inc. Grows Position in Eli Lilly and Company $LLY - Daily Political
How to invest in healthcare stocks without picking the next Eli Lilly
Eli Lilly and Company $LLY Holdings Lifted by Veracity Capital LLC - Daily Political
HWG Holdings LP Buys 6,647 Shares of Eli Lilly and Company $LLY
Isomorphic Labs reportedly seeks funding at a valuation of at least $40 billion
Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response
Wealth Enhancement Trust Services Inc. Sells 579 Shares of Eli Lilly and Company $LLY - Markets Daily
Wealth Enhancement Trust Services Inc. Reduces Stock Holdings in Eli Lilly and Company $LLY - Zolmax
Canandaigua National Trust Co of Florida Acquires 16,555 Shares of Eli Lilly and Company $LLY - Zolmax
16,555 Shares in Eli Lilly and Company $LLY Bought by Canandaigua National Trust Co of Florida - Markets Daily
Eli Lilly and Company $LLY Stock Sold by Bank & Trust Co - Markets Daily
Lake Hills Wealth Management LLC Purchases New Holdings in Eli Lilly and Company $LLY
Eli Lilly and Company $LLY Shares Sold by Bank & Trust Co
Eli Lilly and Company $LLY Stock Sold by American National Bank & Trust - Markets Daily
LLY Maintained by Morgan Stanley -- Price Target Raised to $1430
Eli Lilly and Company (NYSE:LLY) Stock Jumps 2.5% - Should You Buy? - Daily Political
American National Bank & Trust Sells 532 Shares of Eli Lilly and Company $LLY - Stock Observer
Lilly's Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound
Top Healthcare Stocks To Watch Now - October 7th - Daily Political
Eli Lilly and Company (NYSE:LLY) and Fortress Biotech (NASDAQ:FBIO) Critical Review - Markets Daily
Eli Lilly and Company $LLY Stake Raised by RVW Wealth LLC - Zolmax
Eli Lilly and Company $LLY Position Increased by RVW Wealth LLC - Markets Daily
Congress Asset Management Co. Buys 1,454 Shares of Eli Lilly and Company $LLY
Eli Lilly and Company (NYSE:LLY) Stock Jumps 1.3% - What's Next?
Promising Healthcare Stocks To Watch Now - October 6th - Stock Observer
insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab | Morningstar
Top Pharmaceutical Stocks To Follow Now - October 5th - Markets Daily
Eli Lilly and Company $LLY Shares Acquired by Park National Corp OH
Eli Lilly and Company $LLY Stock Sold by Eastern Bank
CapWealth Advisors LLC Acquires 962 Shares of Eli Lilly and Company $LLY
Top Pharmaceutical Stocks To Follow Now - October 5th - Stock Observer
Eli Lilly Expands Gate Bioscience Molecular Gates Collaboration
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions | Morningstar
Best Pharmaceutical Stocks To Add to Your Watchlist - October 4th - Stock Observer
Eli Lilly launches 'Nujoom Al Ghad' to build next generation of Emirati talent in healthcare
Eli Lilly's Valuation Has Changed. Here's What Investors Need to Know
Pharmaceutical Stocks To Watch Now - October 3rd - Zolmax
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories
6,930 Eli Lilly and Company $LLY Shares Sold by CX Institutional
Case: Patents/Procedure (Fed. Cir.)
Lilly, Novo bet on amylin obesity drugs after GLP-1s
"Patient-centric innovation must be central mission of life sciences industry": JP Nadda at BLSA awards
Coastline Trust Co Sells 1,123 Shares of Eli Lilly and Company $LLY
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment | Morningstar
Best Pharmaceutical Stocks To Follow Today - October 1st - Stock Observer
Lilly Reports Foundayo Data Showing Lower Predicted Diabetes And Cardiovascular Risk
Oral GLP-1 Drugs: Novo Nordisk, Eli Lilly Eye India Launch In 2027 | Pharma Stocks In Focus
Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials With Ely Lilly | Morningstar
LLY: Pipeline Promise Remains, Pricing And Legal Risks Now Drive The Bear Case
Lilly's oral GLP-1, Foundayo , was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease | INN
Lilly's Foundayo Shows Cardiovascular Safety, Sustained A1C And Weight Benefits In ACHIEVE-4
Lilly's Foundayo Demonstrates Cardiovascular Safety In Landmark Diabetes Study
Foghorn cuts staff 40% as Lilly terminates SMARCA2 deal | BioWorld
Rose-Hulman Hosts Fall Career Fair With hundreds Employers
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study | Morningstar
Eli Lilly and Company (NYSE:LLY) Stock Falls 1.9% - What's Next?
Promising Pharmaceutical Stocks Worth Watching - September 30th
Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial
Lilly's EBGLYSS Shows Rapid Skin Clearance And Symptom Relief In Phase 3b Study
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis | Morningstar
Eli Lilly and Company (NYSE: LLY) EloraTZP Adds Weight Loss and More Dropouts - Stock Observer
Lilly's Retatrutide Drives Significant Weight Loss And A1C Improvement In Phase 3 Diabetes Study
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes | Morningstar
Eli Lilly (LLY) Stock: Foundayo Outpaces Novo's Ozempic in Latest Diabetes Data
Promising Healthcare Stocks To Follow Today - September 29th - Stock Observer
Lilly Reports Orforglipron Results Versus Oral Semaglutide 25 mg in Indirect Analysis
Lilly's Zepbound was associated with more weight loss than Wegovy HD in a new indirect treatment comparison | INN
Lilly's Foundayo Tops Oral Semaglutide In New Diabetes Analysis
What Could Eli Lilly (LLY) New Cancer Win And Deal Shift Mean?
Global Overseas Giants Rush to Acquire Upstream Medical Isotopes - Why Chinese Nuclear Pharmaceutical Enterprises Are Not Rushing?
Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political
Alcohol Use Disorder Market Outlook Shows Significant Expansion Across the 7MM Through 2036 | ABNewswire
Eli Lilly and Company (NYSE:LLY) Given New $1,500.00 Price Target at JPMorgan Chase & Co. - Daily Political
Promising Pharmaceutical Stocks To Research - September 28th - Zolmax
Can Roche's Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Healthcare Stocks To Add to Your Watchlist - September 28th - Zolmax
Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,500.00
Bharat Life Sciences Award 2026 Innovation Summit to explore India's next phase of life sciences growth
Eli Lilly and Company (LLY) is Expanding Beyond its Biggest Growth Drivers. Can it Sustain the Momentum?
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes
Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations
China's InnoCare inks $3.5 B deal with Eli Lilly to develop new medicines
A New Wave of Senior Patients Could Extend Lilly's GLP-1 Growth Story
EliLilly News
GE Vernova Stock Forecast & Analysis: Will Data-Centre Power and Grid Investment Fuel the Next Rally?
Samsung Electronics Stock Price Forecast 2026–2027: Can Record Q3 Profit Extend the AI Rally?
GBP/USD Forecast: Can Sterling Hold 1.32 as Fed Rate-Hike Bets Rise?
AUD to USD Forecast 2026–2030: Can the Aussie Reclaim 0.71 After the RBA’s Fourth Rate Hike?
Advanced CFD Trading Tools Review: Which Tools Can Improve Your Trading Decisions?
Latest news
Show more
Delta Earnings Preview: Can Strong Travel Demand Offset Oil Above $104?
Oil Prices Surge as Brent Tops $104 on Iran Tensions and Hurricane Isaias
US Consumer Sentiment Preview: Will Rising Inflation Expectations Keep the Fed Hawkish?
Tesla Stock Slips Despite $500 Price Target as FSD Delays and Spending Stay in Focus
EUR/USD Holds Near a 17-Month Low as France’s Debt Crisis Weighs on the Euro
AI Stocks Tumble as OpenAI Revenue Run Rate Comes In $20 Billion Below Earlier Reports
